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Abstract
Background: The copper intrauterine device (IUD) is under-utilised in South Africa, where injectable progestin
contraception (IPC) dominates contraception usage. There is a lack of robust comparative data on these
contraceptive options to inform policy, programs, clinical counseling, and women’s choices.
Methods: Within the context of a South African program to increase women’s access to the IUD, we conducted a
pragmatic, open-label, parallel-arm, randomised controlled trial of the IUD versus IPC at two South African hospitals.
The target sample size was 7,000 women and the randomisation ratio was 1:1. The random sequence was
computer-generated and group allocation was concealed in sealed, opaque, consecutively-numbered envelopes.
Counselled, consenting women attending termination of pregnancy services were randomly assigned to IUD or IPC
immediately post-termination. Condoms were promoted for the prevention of sexually-transmitted infections. The
primary outcome was pregnancy; secondary outcomes were discontinuation, side-effects, and HIV acquisition and
disease progression. Pregnancy and discontinuation outcomes are reported here.
Results: The trial closed early with 2,493 participants randomised (IUD = 1,247, IPC = 1,246), due to international
concerns regarding a possible association between IPC and HIV acquisition. Median follow-up was 20 months; 982
and 1000 participants were followed up in the IUD and IPC groups, respectively. Baseline group characteristics were
comparable. Pregnancy occurred significantly less frequently among women allocated to the IUD than IPC: 56/971
(5.8 %) versus 83/992 (8.4 %), respectively; risk ratio (RR) 0.69, 95 % confidence interval (CI) 0.50 to 0.96; P = 0.025.
There were more protocol violations in the IUD group; however, discontinuation rates were similar between IUD
and IPC groups (141/855 [16.5 %] and 143/974 [14.7 %], respectively). Women in the IUD group were more likely to
discontinue contraceptive use due to abdominal pain or backache and non-specific symptoms, and those in the
IPC group due to oligo- or amenorhoea and lack of sexual activity.
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Conclusions: The IUD was significantly more effective in preventing pregnancy than IPC. Efforts to expand
contraception options and improve access to the IUD in settings where it is under-utilised are worthwhile. This trial
shows that randomising long-acting, reversible contraceptives is feasible.
Trial registration: Pan African Clinical Trials Registry number PACTR201409000880157 (04-09-2014).
Keywords: DMPA, IUD, Random
Background
More than 4,000 terminations of pregnancy are performed
each year in the East London/Mdantsanes area of South
Africa and, in a survey of postnatal women attending local
hospitals and clinics, two thirds of births were unintended
[1]. Like most of South Africa, women utilising services at
Frere and Cecelia Makiwane Hospitals and clinics have a
limited choice of contraceptives and injectable progestin
contraception (IPC), including depot medroxyprogester-
one acetate (DMPA) and norethisterone enantate (NET),
account for most contraception use. A common reason
for discontinuation of contraception by women attending
these services is dissatisfaction with the contraceptive
method. The World Health Organization (WHO) con-
tinues to highlight the need for a wider variety of highly
effective contraceptive methods to be available to women
living in low and middle-income countries (LMICs) [2].
The copper intrauterine device (IUD) is a well-
established, highly effective method of contraception;
however, availability issues, staff capacity, provider atti-
tude, and perception of side effects have held back its
use in many LMICs, including South Africa [3–5]. In
2005, we initiated a program at Frere and Cecelia
Makiwane Hospitals and clinics to expand contraceptive
options to include the copper IUD (SMB® Model TCu
380A), which was previously unavailable in our services.
However, we found comparative data on the relative
contraceptive effectiveness of the IUD and IPC to be
insufficient for adequate counselling of prospective
users: Limited evidence from a 2010 Cochrane review
suggested that the IUD was more effective in preventing
unintended pregnancy than hormonal contraception
(including IPC), but had not been further elucidated [6];
and observational data were subject to confounding as
contraceptive choice often varies according to factors re-
lated to the likelihood of pregnancy. To enhance the
knowledge base for our counselling and promotion of
wider contraception options, we designed a pragmatic
trial within our routine contraceptive services to com-
pare effectiveness, method discontinuation, and reasons
for discontinuation, of the newly introduced method
(IUD) with that of the most widely-used method (IPC).
As secondary outcomes, we also assessed side effects,
HIV acquisition and HIV/AIDS disease progression,
which we intend to report separately.
Methods
Study design and participants
The trial was a pragmatic, open-label, parallel arm ran-
domised controlled trial conducted at two Eastern Cape
hospitals, Frere Hospital (FH) and Cecelia Makiwane
Hospital (CMH), in South Africa. Recruitment began on
6 July 2009 and ended on 8 November 2012. Women at-
tending termination of pregnancy services at the study
sites, who met the inclusion criteria and requested long-
term contraception with no personal preference for a
particular method, were counselled in their home lan-
guage and offered participation in the trial. Women were
eligible if they intended to continue contraception for at
least one year, were ≥ 16 years old, had no evidence of
active pelvic infection on history and clinical examin-
ation, had no contraindications to IPC or IUD use, were
prepared to use either method of contraception, under-
stood the patient information form, and were willing to
sign informed consent. All women were offered counsel-
ling and voluntary HIV testing at baseline and at follow-
up, according to national health policy, using rapid tests
or laboratory-based ELISA tests. Those with positive re-
sults were offered a CD4 count and treatment according
to national health guidelines.
Ethics, consent, and permissions
Ethical approval for the trial was obtained from the
University of the Witwatersrand Committee for Research
on Human Subjects, South Africa, on the 25 April 2008,
clearance certificate M080466. Signed informed consent to
participate in the study was obtained from all participants.
Randomisation
An allocation list was prepared using a computer-
generated random sequence in balanced blocks of variable
size and with a randomisation ratio of 1:1. Allocation slips
were inserted into consecutively-numbered, opaque enve-
lopes and sealed by a member of staff not involved in the
trial. The randomisation list was sealed in a signed enve-
lope by the same staff member for safekeeping. The
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randomisation envelopes were distributed to the study
sites in batches of 100. Women who agreed to participate
were entered onto a trial register and then enrolled by
opening the next numbered, sealed envelope. The point of
trial entry was at the opening of the envelope.
Interventions
Women were fully counselled about their allocated
contraception method prior to its administration. In the
IUD group, the IUD was inserted after termination of
pregnancy, which was usually performed by manual vac-
uum aspiration by the hospital staff following routine
procedures. Antibiotic prophylaxis was not used. The
women were offered two options regarding the string
placement after full counselling about the relative bene-
fits of each: strings protruding from the cervix by about
2 cm, or strings inserted completely within the uterine
cavity or removed. The reason for offering these options
is that many women in our services prefer their contra-
ception to be confidential. In the IPC arm, women were
counselled regarding the need for repeat injections at
regular intervals. The first injection was administered by
hospital staff according to routine practice and, in most
instances, DMPA was used. However, as this was a prag-
matic trial within the routine contraception services, al-
lowance was made for the use of NET at the discretion
of the provider. Women received no additional re-
minders to support continuation with the allocated
contraception method, and no payments or other incen-
tives were offered, other than payment of transport costs
for the final visit at 12 months post-enrolment.
Outcomes
The primary outcome was pregnancy. Secondary out-
comes were method discontinuation, side effects, HIV
acquisition, and HIV/AIDS disease progression. Preg-
nancy and discontinuation outcomes are reported in
this paper.
Data collection
Professional nurses who worked as research assistants
completed a Good Clinical Practice certification course
before trial commencement. Participant baseline details
were entered onto a paper case report form (CRF), in-
cluding demographic data, medical history, and baseline
data relevant to the follow-up questionnaire (including
sexual activity and potential side effects). Follow-up
questionnaires were administered by the research assis-
tants to participants by telephone at three, six, nine and
12 months after randomisation. The CRF and question-
naire were piloted before the main trial. The actual
contraceptive method received after randomisation was
collected retrospectively from family planning registers
at the two hospitals. Participants were requested to
attend an interview at the hospital 12 months after en-
rolment, failing which the interview was conducted by
telephone. Initial and final contraceptive methods used
were confirmed with the participant at the last interview.
Other questions at this interview included whether the
participant had been pregnant since joining the study,
the outcome of the pregnancy, and what contraceptive
methods had been used since joining the study, as well
as reasons for discontinuation. Attempts to contact
women who did not return for follow-up were continued
until study closure in June 2014. Research assistants ad-
vised participants to attend the relevant health facility
for any health concerns.
Sample size and analysis
The sample size was calculated based on the primary out-
come. To detect a reduction in unplanned pregnancy from
2.5 % to 1.5 %, we calculated that we needed 6,546 partici-
pants (alpha = 0.05, beta = 0.20; Epi Info™ statistical soft-
ware version 7). To allow for loss to follow-up, we
planned to recruit a total sample size of 7,000 women.
Intention-to-treat analysis was performed for the pri-
mary outcome (pregnancy) using Epi Info™ statistical soft-
ware. Discontinuation rate was defined as the proportion
of women who did not continue use of the allocated
method to follow-up, out of the women initiating the allo-
cated method and this analysis was, thus, per protocol.
Baseline characteristics were compared between en-
rolled groups, as well as those with follow up of 12 months
or more. For categorical variables, the rates of outcome
events were compared as risk ratios (RR) with 95 % confi-
dence intervals (CI). P-values were calculated using the
Chi-squared test with Mantel-Haenszel correction or, for
small numbers, the Fisher’s exact test. P values of less than
0.05 were regarded as statistically significant.
Trial registration
Registration of the protocol with the South African
National Clinical Trials Register was undertaken on
15 September 2008 (Verification Code: 0–953). It
was subsequently found not to have been logged by
the system, and was re-registered with the Pan
African Clinical Trials Registry on 4th September 2014
(PACTR201409000880157). (http://apps.who.int/trialsearch/
Trial2.aspx?TrialID=PACTR201409000880157).
Results
The trial closed early due to international concerns re-
garding a possible association between DMPA and HIV
acquisition, following publication of an observational
study reporting increased HIV acquisition among women
who chose DMPA [7], and the subsequent plan by inter-
national stakeholders to conduct a large, multicentre trial
that could address the DMPA/HIV question [8].
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At closure, 2,493 of the target sample had accrued
(36 %), with 1,247 and 1,246 women randomised to the
IUD and IPC groups, respectively. An additional 19 ran-
domisation envelopes could not be linked to participants
(see CONSORT Fig. 1). Baseline data for the IUD and
IPC groups were well matched (Table 1). Data on the
primary outcome were available for 1,963 participants
(78.7 %). The median time to final interview was
20 months (interquartile range 15 to 28). In the IUD
group, 56 out of 971 women (5.8 %) became pregnant
during follow-up compared with 83 out of 992 women
(8.4 %) in the IPC group (risk ratio (RR) 0.69, 95 % con-
fidence interval (CI) 0.50 to 0.96; P = 0.025). There were
no statistically significant differences between groups for
the type of pregnancy outcome (Table 2).
Data on discontinuation were available for 982 women
(78.7 %) in the IUD group and 1000 women (80.3 %) in
the IPC group. In the IUD group, 855 (87.1 %) of the
982 women received an IUD as allocated; the other 127
women (12.9 %) received a non-allocated method
(protocol violations), which was an IPC in most (125)
cases. In the IPC group, 974 out of 1000 women
(97.4 %) received an IPC as allocated, with 85.5 % receiv-
ing DMPA; the remainder received NET. Twenty-three
out of the 26 women in the IPC group receiving a non-
allocated method (protocol violations) received an IUD,
and follow-up data did not distinguish between DMPA
and NET. At the final follow-up interview, 729 women
(74.2 %) out of 982 women in the IUD group were using
an IUD, compared with 831 (83.1 %) out of 1000 women
in the IPC group (intention-to-treat). Loss to follow-up
was relatively high and, in the worse case scenario, if all
those lost to follow-up were not using the allocated
method, the percentage of women using the allocated
method at follow-up in the IUD and IPC groups was
58.5 % and 66.7 %, respectively. However, among women
who initiated their allocated treatment as per protocol,
discontinuation at a median follow-up of 20 months was
not statistically significantly difference between the IUD
and the IPC groups (141/855 women [16.5 %] versus
143/974 women [14.7 %], respectively; RR 1.12, 95 % CI
0.91 to 1.39; P = 0.29) (Table 3).
Women in the IUD group were more likely than those
in the IPC group to discontinue contraceptive use due to
abdominal pain or backache (P = 0.00005) and non-
specific symptoms (P = 0.004), and those in the IPC group
were more likely to discontinue due to oligo-or amenor-
hoea (P = 0.004) and lack of sexual activity (P = 0.0002)
(Table 4). Expulsion of the IUD was given as the reason
for discontinuation in 26/135 (19.3 %) women who dis-
continued IUD use, giving an expulsion rate of 3 %. Two
women in the IUD group and four women in the IPC
group were reported to have died during the follow-up
period. Information on these women is shown in Table 5.
Discussion
As mentioned above, during the conduct of our trial an
observational study published findings of increased HIV
acquisition among women who chose DMPA contracep-
tion, which gained wide media attention [7]. Trial inves-
tigators attended international stakeholder consultations,
where there were calls for a large, multicentre trial to
conclusively answer the questions on the effects of hor-
monal contraception on HIV acquisition and disease
progression [2]. In such a trial, any evidence relating to
DMPA should be robust and distinct from other long-
acting, progestin contraceptives. As the current prag-
matic trial was unable to unequivocally answer the
DMPA/HIV question due to the allowance of DMPA or
NET in the IPC group, we stopped recruitment in
November 2012. We followed up the reduced sample as
planned with the aim of using these data to inform the
design of the requisite, more robust trial [8].
Nevertheless, the sample size was adequate to assess
the primary outcome due to the occurrence of higher
than expected pregnancy rates in this trial. In contracep-
tive guidelines, contraceptive failure with typical use is
considered to be about six pregnancies per 100 women-
years with IPC use, and one per 100 women-years with
IUD use [9]. The estimate for IPC failure is supported
by our findings, and those of a recent observational
study of contraceptive use in South Africa, which re-
ported pregnancy rates with IPC of 4.4 per 100 women-
years [3]. However, pregnancy rates in women allocated
to IUD use in our study, although significantly lower
with the IUD than IPC, were higher than expected. This
was probably partly due to over-estimation on intention-
to-treat analysis, as 13 % of women allocated to the IUD
Allocated to IPC (n=1246) Allocated to IUD (n=1247)
Lost to follow-up (n=246) Lost to follow-up (n=265)
Analysed at median of 20
months (n=1000)
Received initially:
IPC (n=974)
IUD (n=23)
OC (n=3)
Analysed at median of 20
months (n=982)
Received initially:
IUD (n=855)
IPC (n=125)
OC (n=2)
Participants randomised (n=2493)
Fig. 1 CONSORT diagram showing the flow of participants
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group received IPC. Thus, our findings provide robust
evidence that allocation to the IUD is more effective
than allocation to IPC in preventing unintended preg-
nancies in South Africa. This has important implications
for contraceptive policy in South Africa, where injectable
progestin contraception accounts for the vast majority of
contraception in the public sector and efforts to improve
the method mix have had limited success.
A large study of more than 200,000 women from 14
developing countries reported a median probability of
IUD discontinuation of 13.2 % [10]. Higher rates of IUD
and IPC discontinuation (and unintended pregnancy)
have been observed among women with a history of ter-
mination of pregnancy [11–14]. In two post-termination
cohorts of women who chose IPC, discontinuation rates
as high as 64 per 100 woman-years, and 84 % were re-
ported [13, 14]. As all the participants in our trial were
recruited post-termination of pregnancy, this factor may
have contributed to contraceptive failure and discontinu-
ation in our trial.
Due to the pragmatic nature of this trial, loss to
follow-up was relatively high, at around 20 % in both
intervention groups. This limitation could have lead to
an under-estimation of method discontinuation due to
differential loss of women who discontinued their allo-
cated method. For this reason we reported the propor-
tion of women using each method out of those with
known follow up data, as well as for of the intervention
groups as a whole. Baseline characteristics were compar-
able, therefore, loss to follow-up did not appear to have
been differential between random allocation groups. An-
other limitation of the trial was the high number of
protocol violations in the IUD group; 12.7 % of women
with follow-up data in the IUD group received the IPC
after randomisation instead of the IUD. The reasons for
protocol violations were not recorded, but could have
been due to women declining the IUD after randomisa-
tion in favour of the more familiar method (IPC), or dif-
ficulties with IUD insertion, or provider barriers. Of the
participants with data on previous contraceptive use,
Table 1 Baseline data expressed as numbers (%) or mean values (standard deviation (SD))
IUD group IPC group
n (%) or mean [SD] N n (%) or mean [SD] N
Age in years 26.7 [6.3] 1234 26.4 [6.1] 1239
Weight in kgs 71.7 [17.9] 1214 70.2 [16.4] 1220
Previous miscarriage 107 (8.7) 1235 100 (8.1) 1232
Previous caesarean section 163 (13.3) 1230 146 (11.8) 1236
Previous pelvic sepsis 241 19.6) 1230 237 (19.2) 1232
Hypertension 14 (1.1) 1236 11 (0.9) 1242
Diabetes mellitus 5 (0.4) 1236 6 (0.5) 1241
HIV positive 236 (21.2) 1110 240 (21.6) 1118
Previous contraception use
-IPC 801 (71.1) 1126 824 (72.5) 1136
-oral contraceptive pill 90 (7.7) 1176 64 (5.4) 1184
-IUD 2 (0.2) 1177 1 (0.1) 1188
IUD intrauterine device, IPC injectable progestin contraception
Table 2 Pregnancy rates and outcomes
IUD group (N = 971) IPC group (N = 992) RR 95 % CI P-value (M-H)
n % n %
Pregnancy (total) 56 5.8 83 8.4 0.69 0.50 to 0.96 0.025
Pregnancy outcome:
Birth 29 3 41 4.1 0.72 0.45 to 1.15 0.17
Miscarriage 3 0.3 3 0.3
Termination 2 0.2 2 0.2
Ectopic 0 0 1 0.1
Ongoing 16 1.6 29 2.9 0.56 0.31 to 1.03 0.059
Unknown 6 0.6 7 0.7
IUD intrauterine device, IPC injectable progestin contraception, RR risk ratio, CI confidence interval, M-H mantel-haenszel chi square 2-tail
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Table 3 Allocated and actual contraception method and discontinuation
Allocated method
IUD IPC
Actual method/s used N % final method known % total N % final method known % total
Initial method used: IUD 855 87.1 % 68.6 % 23 2.3 % 1.8 %
Initial method/final method:
IUD/IUD 714 72.7 % 0.1 % 21 2.1 % 1.7 %
IUD/IPC 32 3.3 % 2.6 % 0 0.0 % 0.0 %
IUD/OC 4 0.4 % 0.3 % 0 0.0 % 0.0 %
IUD/Sterilisation 1 0.1 % 0.1 % 0 0.0 % 0.0 %
IUD/none 104 10.6 % 8.3 % 2 0.2 %
Initial method used: IPC 125 12.7 % 10.0 % 974 97.4 % 78.2 %
IPC/IPC 105 10.7 % 8.4 % 831 83.1 % 66.7 %
IPC/IUD 15 1.5 % 1.2 % 11 1.1 % 0.9 %
IPC/OC 0 0.0 % 0.0 % 11 1.1 % 0.9 %
IPC/sterilisation 0 0.0 % 0.0 % 3 0.3 % 0.2 %
IPC/none 5 0.5 % 0.4 % 118 11.8 % 9.5 %
Initial method used: Other 2 0.2 % 0.2 % 3 0.3 % 0.2 %
Initial method/final method:
OC/OC 2 0.2 % 0.2 % 3 0.3 % 0.2 %
Final method known 982 78.7 % 1000 80.3 %
Final method unknown 265 21.3 % 246 19.7 %
Total randomised 1247 1246
IUD intrauterine device, IPC injectable progestin contraception
Table 4 Discontinuation and reasons
Reason for discontinuation (total) IUD group IPC group RR 95 % CI P-value (M-H)
135 147
Want baby/married 19 14.1 26 17.7 0.8 0.46 to 1.37 0.41
Fell pregnant 3 2.2 1 0.7
Abdominal pain/backache 21 15.6 3 2 7.62 2.33 to 25 0.00005
Heavy menstruation 9 6.7 13 8.8 0.75 0.33 to 1.71 0.5
Scanty/no menstruation 0 0 9 6.1 0 NE 0.004 (FE)
Not sexually active 11 8.1 36 24.5 0.33 0.18 to 0.63 0.0002
Weight gain 0 0 3 2
Weight loss 1 0.7 0 0
Partner request 1 0.7 0 0
Discomfort during intercourse 1 0.7 0 0
Infection 2 1.5 0 0
Itchy vulvae/discharge 2 1.5 0 0
Headaches 0 0 1 0.7
Non-specific symptoms 12 8.9 2 1.4 6.5 1.49 to 29 0.004
Using condoms 1 0.7 4 2.7
Suspected cancer 1 0.7 0 0
No reason given 25 18.5 49 33.3 0.53 0.35 to 0.82 0.003
IUD came out 26 19.3 0 0
IUD intrauterine device, IPC injectable progestin contraception, RR risk ratio, CI confidence interval, M-H mantel-haenszel chi square 2-tail
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1625 had previously used IPC versus only three previ-
ously using the IUD (Table 3). Whilst protocol violations
may have underestimated differences between contra-
ceptive methods on pregnancy rates, in intention-to-
treat analysis they are unlikely to have over-estimated
effect differences.
While individual choice is a cornerstone of contracep-
tive services, this trial demonstrates that after counseling
on different contraceptive options many women did not
have a specific preference for a contraceptive method and
were willing to agree to randomisation without any finan-
cial remuneration or other benefits. Although initial com-
pliance in the IUD group was sub-optimal (87 %), the
acceptability of randomisation is supported by the fact
that discontinuation of allocated methods were compar-
able with observational studies in which women had
chosen their contraceptive method [10–14]. No trial-
related steps were taken to support adherence to the allo-
cated contraception method, and no payments or other
incentives were offered, other than payment of transport
costs for the final visit at 12 or more months post-
randomisation. In addition, the provision and follow up of
the allocated contraceptive method took place within the
routine health service. The advantage of this was that rela-
tive discontinuation rates and contraceptive effectiveness
were more likely to reflect the ‘typical-use’ effect of these
methods in routine practice (though absolute rates might
differ from women choosing a specific method). The dis-
advantage was that follow-up was less efficient and proto-
col violations were higher than might have been achieved
with a more intensive research intervention.
Conclusions
The IUD was more effective than IPC in a post-
termination of pregnancy setting in South Africa. Disonti-
nuation rates with the IUD were comparable to the more
familiar and widely accepted IPC, suggesting that efforts
to expand contraception method choice and overcome
user and provider barriers to IUDs are worthwhile. Study
limitations such as protocol violations may have led to an
under-estimation of differences in the primary outcome,
but over-estimation is unlikely. This research supports the
feasibility of conducting a large, multi-centre randomised
trial to address the DMPA/HIV question.
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